PuSH - Publication Server of Helmholtz Zentrum München

Feger, M.* ; Meier, L.* ; Strotmann, J.* ; Hoene, M.* ; Vogt, J.* ; Wisser, A.* ; Hirschle, S.* ; Kheim, M.J.* ; Hocher, B.* ; Weigert, C. ; Föller, M.*

Endothelin receptor B-deficient mice are protected from high-fat diet-induced metabolic syndrome.

Mol. Metab. 80:101868 (2023)
Publ. Version/Full Text DOI PMC
Open Access Gold
Creative Commons Lizenzvertrag
Endothelin receptor B (ETB) together with ETA mediates cellular effects of endothelin 1 (ET-1), an autocrine and endocrine peptide produced by the endothelium and other cells. It regulates vascular tone and controls kidney function. Metabolic syndrome is due to high caloric intake and is characterized by insulin resistance, dyslipidemia, and white adipose tissue (WAT) accumulation. ETA/ETB antagonism has been demonstrated to favorably influence insulin resistance. Our study explored the role of ETB in metabolic syndrome. Wild type (etb+/+) and rescued ETB-deficient (etb-/-) mice were fed a high-fat diet, and energy, glucose, and insulin metabolism were analyzed, and hormones and lipids measured in serum and tissues. Cell culture experiments were performed in HepG2 cells. Compared to etb+/+ mice, etb-/- mice exhibited better glucose tolerance and insulin sensitivity, less WAT accumulation, lower serum triglycerides, and higher energy expenditure. Protection from metabolic syndrome was paralleled by higher hepatic production of fibroblast growth factor 21 (FGF21) and higher serum levels of free thyroxine (fT4), stimulators of energy expenditure. In conclusion, ETB deficiency confers protection from metabolic syndrome by counteracting glucose intolerance, dyslipidemia, and WAT accumulation due to enhanced energy expenditure, effects at least in part dependent on enhanced production of thyroid hormone/FGF21. ETB antagonism may therefore be a novel therapeutic approach in metabolic syndrome.
Impact Factor
Scopus SNIP
Web of Science
Times Cited
Altmetric
8.100
0.000
1
Tags
Annotations
Special Publikation
Hide on homepage

Edit extra information
Edit own tags
Private
Edit own annotation
Private
Hide on publication lists
on hompage
Mark as special
publikation
Publication type Article: Journal article
Document type Scientific Article
Keywords Fgf21 ; Insulin ; Thyroid Hormone ; Triglyceride; Improves Insulin Sensitivity; Etb-receptor; Ppar-alpha; Antagonists; Inflammation; Fgf21
Language english
Publication Year 2023
HGF-reported in Year 2023
ISSN (print) / ISBN 2212-8778
e-ISSN 2212-8778
Quellenangaben Volume: 80, Issue: , Pages: , Article Number: 101868 Supplement: ,
Publisher Elsevier
Publishing Place Amsterdam
Reviewing status Peer reviewed
POF-Topic(s) 90000 - German Center for Diabetes Research
Research field(s) Helmholtz Diabetes Center
PSP Element(s) G-502400-001
Grants Deutsche Forschungsgemeinschaft (DFG)
Scopus ID 85182428533
PubMed ID 38159882
Erfassungsdatum 2024-01-07